ENGAGE: A Clinical trial of Dupilumab in Patients with Eosinophilic Gastritis

Trial ID:
IRB-23-8251
Fouad Joseph Moawad, MD

Inclusion Criteria

Patients must:

  • Be male or female, over 12 years of age
    Have documented endoscopic biopsy supporting a pathologic diagnosis of Eosinophilic Gastritis/Eosinophilic Duodenitis at least 3 months prior to screening

Exclusion Criteria

Patients must not:

  • Have a history of achalasia, Crohn’s disease, eosinophilic colitis, ulcerative colitis, celiac disease, and prior gastric or duodenal surgery
    Have a history of malignancy within 5 years prior to screening
    Have previously received treatment with dupilumab

Additional Info

Patients will be randomized (like the flip of coin) to receive either Dupixent or placebo. Dupixent is approved by the U.S. FDA for various other inflammatory allergic diseases such as atopic dermatitits (AD), chronic rhinosinusitis with nasal polyposis (CRSwNP), and asthma, but not for EoG.

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org